Advanced in Febrile Neutropenia

Agnes S. Jager

Erasmus MC
Rotterdam, ZH, NL 
Advanced in Febrile Neutropenia
Erasmus MC
Rotterdam, ZH, NL 
OverviewLocationsClinical Research

Overview

Agnes Jager practices in Rotterdam, Netherlands. Ms. Jager is rated as an Advanced expert by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Breast Cancer, Ovarian Cancer, Febrile Neutropenia, Mastectomy, and Lymphadenectomy.

Her clinical research consists of co-authoring 334 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Febrile Neutropenia.

Gender
Female

Locations

Erasmus MC
Rotterdam, ZH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug
Study Drug: PTC-Pz
Study Phase: Phase 2
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients with Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients with Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drugs: ddAC-CP-Olaparib, ddAC-mini CTC
Study Phase: Phase 3
Phase II Study With PARP Inhibitor Veliparib (ABT-888) in Patients With Increased Risk of Homologous Recombination Deficiency to Determine the Value of an (Ex-vivo) RAD51 Assay as a Biomarker
Phase II Study With PARP Inhibitor Veliparib (ABT-888) in Patients With Increased Risk of Homologous Recombination Deficiency to Determine the Value of an (Ex-vivo) RAD51 Assay as a Biomarker
Enrollment Status: Withdrawn
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: December 15, 2022
Intervention Type: Drug
Study Drugs: G1T48, Palbociclib
Study Phase: Phase 1
A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging
A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging
Enrollment Status: Completed
Publish Date: August 18, 2022
Intervention Type: Drug
Study Phase: Phase 1
AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial
AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial
Enrollment Status: Terminated
Publish Date: July 19, 2022
Intervention Type: Drug
Study Drugs: Carboplatin, Atezolizumab
Study Phase: Phase 2
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients: the ABC Study
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients: the ABC Study
Enrollment Status: Terminated
Publish Date: July 18, 2022
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 2
View 7 Less Clinical Trials

332 Total Publications

Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Journal: Nature
Published: July 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Jager's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile